Drugs / E7 TCR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04411134 | May → Jul 2020 | cervical intraepithelial neoplasia | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04044950 | Jul 2019 → Sep 2020 | human papilloma virus infection, oropharynx cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7 TCR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04411134 ↗ |
| Modality | Cell therapy | “This therapy is a type of treatment in which a participant s T cells (a type of immune system white blood cell) are changed in the laboratory to attack cancer cells.” NCT04044950 ↗ |
| Route | Other | “intralesional injection of E7 TCR T cells” NCT04411134 ↗ |